Experimental AML combo trial halted early – what happened?
NCT ID NCT03055286
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called CWP232291 combined with the standard chemotherapy cytarabine in 15 adults with acute myeloid leukemia (AML) that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for signs of effectiveness, but it was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CWP232291 (an experimental drug) combined with cytarabine (a standard chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with AML that has come back or not responded to other therapies.
What could go wrong
This was a very early, small trial that was terminated early, so we don't know if the drug works or is safe. The results may never be published.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Songpa-Gu, South Korea
-
Samsung medical center
Seoul, Gangnam-gu, South Korea
-
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Washington
Seattle, Washington, 98195, United States